OrbiMed Advisors Mergers and Acquisitions Summary

Private Equity Firm Profile

OrbiMed Advisors’ most common sectors for investment arelife science (60%) and healthcare services (20%) . The Firm’s most common investment types include venture (40%) and growth capital (40%). In total, OrbiMed Advisors has invested in 2 US states and 3 different countries.

The Firm’s most common exit type is ipo (50%). OrbiMed Advisors’ largest (disclosed) exit occurred in 2018 when it sold GENEWIZ for $450M.

Join Mergr to view OrbiMed Advisors’ full profile and discover more large private equity firm investors just like it.

M&A Summary

  • M&A Total Activity9
    • M&A Buy Activity5
    • M&A Sell Activity4
  • Total Sectors Invested 3
  • Total Countries Invested 3
  • M&A Buy/Sell Connections 6
  • M&A Advisors 1

OrbiMed Advisors LLC

601 Lexington Avenue, 54th Floor,
New York, New York 10022
United States
(212) 739-6400
www.orbimed.com
info@orbimed.com

OrbiMed Advisors is a global healthcare centric investment firm that invests in medical device, life science, healthcare service, and medical diagnostic companies. OrbiMed maintains three investment disciplines including Public Equity, Private Equity, and Royalty Opportunities. OrbiMed's Public Equity group manages a series of public equity funds, including long/short event-driven funds and closed-end investment trusts that invests across all types of publicly-traded companies, from biopharmaceuticals to medical devices and healthcare services worldwide. OrbiMed's Private Equity group invests in start-ups through growth equity financings. OrbiMed prefers to be the lead investor and will consider opportunities across North America, Asia, Europe and Israel. OrbiMed's Royalty practice provides commercial-stage healthcare companies with non-dilutive structured debt capital. OrbiMed was formed in 1989 and is based in New York City.


Investment Criteria

Sectors of Interest: Healthcare Services, Life Science, Medical Products

Target Transaction Types: Growth Capital, Venture

Geographic Preferences: East US, Midwest US, South US, West US, Canada, United Kingdom, Western Europe, Nordic, Asia/Pacific, Australia/New Zealand, Central Asia/India, Middle East

Transaction Criteria Min Max
Target Revenue - -
Target EBITDA - -
Investment Size - -
Enterprise Value - -

M&A Summary

Buy vs Sell

Year ≤ '19 '20 '21 '22 '23 '24 T
Buy (0.0/yr) # 5 - - - - - 5
Sell (0.2/yr) # 3 1 - - - - 4
vol $450M $450M
  9

Most Recent M&A

Company Date Value Type
Arcutis Biotherapeutics, Inc. 2020-01-30 - IPO
Westlake Village, California · www.arcutis.com
GENEWIZ, Inc. 2018-09-26 450M USD Trade Sale
South Plainfield, New Jersey · www.genewiz.com
Tricida, Inc. 2018-06-02 - IPO
South San Francisco, California · www.tricida.com
Echosens SAS 2018-03-09 - Secondary Sale
Paris, France · www.echosens.com
Suraksha Diagnostics Pvt. Ltd. 2016-06-10 - Stake Purchase
Kolkata, India · www.surakshanet.com
GENEWIZ, Inc. 2016-01-11 - Growth Capital
South Plainfield, New Jersey · www.genewiz.com
Arcutis Biotherapeutics, Inc. 2016-01-01 - Venture
Westlake Village, California · www.arcutis.com
Echosens SAS 2015-04-29 - Growth Capital
Paris, France · www.echosens.com
Tricida, Inc. 2015-03-05 - Venture
South San Francisco, California · www.tricida.com
View All >>

M&A by Sector

Sector Current # Value All-time # Value
Life Science - - 3 (60%) -
Healthcare Services 1 (100%) - 1 (20%) -
Medical Products - - 1 (20%) -
Total 1 - 5 -

Acquisitions By Geo

State/Country Current # Value All-time # Value
United States - - 3 (60%) -
  California - - 2 (40%) -
  New Jersey - - 1 (20%) -
India 1 (100%) - 1 (20%) -
France - - 1 (20%) -
Total 1 - 5 -

Acquisitions by Deal Type

Type Current # Value All-time # Value
Growth Capital - - 2 (40%) -
Venture - - 2 (40%) -
Stake Purchase 1 (100%) - 1 (20%) -
Total 1 - 5 -

Exits by Deal Type

Type Total # Value
IPO 2 (50%) -
Trade Sale - Public Company 1 (25%) 450M (100%)
Secondary Sale 1 (25%) -
Total 4 $450M

Top M&A Advisors

Legal Deals
DLA Piper
1

Deal Values

sell # Total
$100M to $1B 1 $450M
TOTAL $450M
Largest GENEWIZ, Inc.
$450M (2018-09-26)

M&A Connections

Deals
Acquired from
Investor(s)
20%
1 (20%)
Exited to
Investor(s)
25%
1 (25%)
Strategic(s)
25%
1 (25%)

FAQ

When was OrbiMed Advisors LLC founded?

OrbiMed Advisors LLC was founded in 1989.

What type of investor is OrbiMed Advisors LLC?

OrbiMed Advisors LLC is a private equity firm.

Where is OrbiMed Advisors LLC headquartered?

OrbiMed Advisors LLC is headquartered in New York, New York.

How much capital does OrbiMed Advisors LLC have under management?

OrbiMed Advisors LLC has 14.0B USD under management.

 Subscribe to unlock this and 209,180
investor and company profiles

Sign-up today to get full access

  • check  Unlimited Searches
  • check  Unlimited Profile Views
  • check  Build and Export Lists of
    • PE Backed Companies
    • Direct Investors & Acquirers
    • Advisors
    • Deals
    • & More

What's Mergr?

We built Mergr to save people the arduous and time-consuming process of tracking when companies are bought, sold, and who currently owns them.

Every day, new opportunities emerge around M&A and we help professionals of all types comb through transactions, investors, and corporate acquirers via an easy-to-use web database that is accessible to anyone.

Try us for 1 week free today!

Mergr, the Easiest-to-Use PE and M&A DB


Key Benefits

  • Stay informed on events in your industry
  • M&A research that takes seconds (not all afternoon)
  • Better understand your customers and prospects
  • Discover active buyers (or sellers)
Search
  • 4.6K Private Equity Firms
  • 202K M&A Transactions
  • 205K Companies Involved in M&A
    (Buyer, Seller, or Target)
  • 3.6K M&A Advisors
    (Investment Banks and Law Firms)
  • 81K M&A Contacts
    (PE and M&A Advisors)

Ready to try?

Join FREE for 1 Week

No obligation. Cancel anytime.